Skip to main content

Remote Job Finders (RJF)

Capricor soars on potential FDA review extension, filing amendments

Capricor Therapeutics’ CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel, with the biotech’s stock climbing 68% on the update.

Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study

Sponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the drug seem effective, according to European regulators.
Scroll to top